Oxford and London, UK 3rd June 2020. Enara Bio (formerly Ervaxx), a biotechnology company leveraging its proprietary T-cell/T-cell receptor (TCR) discovery and Dark Antigen platforms to deliver targeted cancer immunotherapies, announces its new name Enara Bio Limited. This new name reflects the companys expanded product discovery and development strategy beyond its initial focus on endogenous retroviral (ERV) antigens for the development of cancer vaccines (hence Ervaxx).

Enara is derived from an Arabic word that means illumination, enlightenment and bringing light into darkness. The company believes this new name more closely illustrates Enara Bios mission as a science-led organization exploring the genomic dark matter as a source of novel cancer-specific T-cell antigens. The rebrand also recognizes the companys new TCR research capabilities, including programs that could enable immune recognition of a broad range of tumor cell types in an HLA-independent fashion, and thus offer broadly applicable T-cell therapies. By building discovery efforts on both sides of the T-cell/cancer-cell interface (the immune synapse), Enara Bio is building a pipeline of cancer immunotherapies for broad patient populations.

The company was founded as Ervaxx Ltd. in late 2016 with an initial focus on the development of therapeutic cancer vaccines utilizing novel antigens derived from endogenous retroviral (ERV) DNA sequences. Since then, and based on breakthrough science coming from both internally-generated and in-licensed insights, Enara Bio has broadened its horizons to include TCR-based immunotherapies targeting an extended cancer-associated antigenic repertoire derived from the entire genomic dark matter, termed Dark Antigens.

To accelerate this evolution, Enara Bio in-licensed patents covering T cells and TCRs reactive to cancer-specific antigens and ligands from Cardiff University in January 2020. These exciting new technologies, while early research-stage, present compelling opportunities to develop immunotherapies with the potential to address a broad range of tumor types independent of the patients genetic background.

Kevin Pojasek, President and CEO of Enara Bio commented:

Our new name Enara Bio reflects the progression of our strategy and capabilities to align more broadly with our purpose of delivering impactful immunotherapies to all cancer patients. Our ground-breaking work in identifying and characterizing Dark Antigens is now joined by other exciting new programs focused on pan-cancer, pan-HLA targets, which greatly expand our opportunities for the development of novel immunotherapies with broad utility across patients with diverse cancers. While we continue to press ahead with these exciting programs internally, we are increasingly seeking partnerships to advance the full diversity of our science and product opportunities.

***

About Enara Bio

Enara Bio (formerly Ervaxx) is a science-led company targeting the T-cell/cancer-cell interface (the immune synapse) to develop new targeted cancer immunotherapies designed to treat a broad patient population.

Enara Bio is exploring the hidden depths of cancer and T-cell biology to discover and characterize novel immunotherapy targets, such as Dark Antigens and MR1-presented ligands. We are pioneering approaches to exploit these targets with TCR-directed T-cell immunotherapy and therapeutic vaccines.

To achieve our mission, we are leveraging our differentiated Dark Antigen and TCR discovery platforms that integrate bioinformatics, immunopeptidomics, metabolomics and immunology in our Oxford, UK-based research lab.

Enara Bio is backed by leading life science investors, including SV Health Investors. We have partnerships with world-class academic institutions, including the Francis Crick Institute, Cardiff University, Johns Hopkins School of Medicine and the University of Oxford, to help drive the leading edge of these new areas of science.

For more information visit: http://www.enarabio.com

Visit link:
Ervaxx rebrands as Enara Bio to reflect a broader emphasis on the discovery and development of novel TCR-based cancer immunotherapies - PharmiWeb.com